Compare RGEN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGEN | MIRM |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 7.2B |
| IPO Year | 1995 | 2019 |
| Metric | RGEN | MIRM |
|---|---|---|
| Price | $186.76 | $91.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $167.67 | $119.85 |
| AVG Volume (30 Days) | ★ 853.9K | 464.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 286.96 | 74.59 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $141,236,000.00 | $19,138,000.00 |
| Revenue This Year | $14.30 | $26.22 |
| Revenue Next Year | $14.52 | $22.04 |
| P/E Ratio | $752.96 | ★ N/A |
| Revenue Growth | ★ 35.10 | N/A |
| 52 Week Low | $100.99 | $63.23 |
| 52 Week High | $188.73 | $130.00 |
| Indicator | RGEN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 62.97 | 37.91 |
| Support Level | $158.15 | $88.08 |
| Resistance Level | $188.73 | $98.03 |
| Average True Range (ATR) | 5.68 | 3.90 |
| MACD | 0.33 | -0.37 |
| Stochastic Oscillator | 94.17 | 10.13 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies. It sells four main product categories: filtration and fluid management is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia-Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.